Evidence map›Paper›PMID 25263941›Full record

ArticleCancer cell2014

Gene body methylation can alter gene expression and is a therapeutic target in cancer.

Xiaojing Yang, Han Han, Daniel D De Carvalho, Fides D Lay, Peter A Jones, Gangning Liang

Open access · bronzeAbstract read
In one paragraph

Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 725 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
725citing papers in PubMed, 2 pooled it
34.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

725 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,231 citations in OpenAlex.

  1. Pooled it
  2. Effect of epigenetics on vitamin D levels: a systematic review until December 2020.Archives of public health = Archives belges de sante publique · 2023
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Epigenetic Patterns in Musculoskeletal Disease: Methylation ofCurrent issues in molecular biology · 2026
    Article
  18. Review
  19. Article
  20. Article

665 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Xiaojing YangDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Han HanDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Daniel D De CarvalhoThe Princess Margaret Cancer Centre, University Health Network, Toronto ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto ON M5G 2M9, Canada.
Fides D LayDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Peter A JonesDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: pjones@med.usc.edu.
Gangning LiangDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: gliang@usc.edu.
University of Southern California · USPrincess Margaret Cancer Centre · CA

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Saul Priceman · 1985 to 2026
$181.4M
MECHANISMS OF DE NOVO METHYLATION IN CANCERR01CA082422 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI JONES, PETER A · 1999 to 2016
$5.1M
Epigenetic Drivers of Cancer (PQ 10)R01CA170550 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI BAYLIN, STEPHEN B., JONES, PETER A · 2012 to 2015
$2.4M
Mechanisms of De Novo Methylation in CancerR37CA082422 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JONES, PETER A · 2009 to 2013
$2.2M
Epigentic Alterations in Pre-malignant Tissue of the BladderR01CA124518 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIANG, GANGNING · 2008 to 2012
$1.3M
NCI NIH HHS P30 CA014089NCI NIH HHS P30CA014089NCI NIH HHS R01 CA082422NCI NIH HHS R01 CA-124518NCI NIH HHS R01 CA124518NCI NIH HHS R01 CA170550NCI NIH HHS R37 CA-082422NCI NIH HHS R37 CA082422
6 · The paper itself

Abstract

DNA methylation in promoters is well known to silence genes and is the presumed therapeutic target of methylation inhibitors. Gene body methylation is positively correlated with expression, yet its function is unknown. We show that 5-aza-2'-deoxycytidine treatment not only reactivates genes but decreases the overexpression of genes, many of which are involved in metabolic processes regulated by c-MYC. Downregulation is caused by DNA demethylation of the gene bodies and restoration of high levels of expression requires remethylation by DNMT3B. Gene body methylation may, therefore, be an unexpected therapeutic target for DNA methylation inhibitors, resulting in the normalization of gene overexpression induced during carcinogenesis. Our results provide direct evidence for a causal relationship between gene body methylation and transcription.

Indexed as

DNA MethylationGene ExpressionCell DivisionColonic NeoplasmsHumansPromoter Regions, Genetic

Identifiers

PMID25263941
PMCPMC4224113
OpenAlexW2055986128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.